Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Stock data | 2023 | Change |
---|---|---|
Price | $16.51 | N/A |
Market Cap | $945.16M | N/A |
Shares Outstanding | 57.25M | 0.39% |
Employees | 2.20K | N/A |
Shareholder Equity | -821.70M | -7.82% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 13.53 | N/A |
P/S Ratio | 0.84 | N/A |
P/B Ratio | -1.15 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.0857 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $1.12B | N/A |
Earnings | $70.40M | N/A |
EPS | 1.22 | N/A |
Earnings Yield | 0.0739 | N/A |
Gross Margin | 0.6691 | N/A |
Operating Margin | 0.1999 | N/A |
Net income margin | 0.0628 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $1.21B | N/A |
Total Debt | $1.64B | N/A |
Cash on Hand | $326.50M | N/A |
Debt to Equity | -2.4779 | 11.68% |
Cash to Debt | 0.1993 | -1.01% |
Current Ratio | $2.12 | -4.04% |